ZYBERNO
Stock Report
Updated Aug 31, 2026

KalVista Pharmaceuticals, Inc. (KALV)

Healthcare • NASDAQ

$27.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
13.0/100
POOR BUSINESS
KalVista Pharmaceuticals, Inc. (KALV) scores 13/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-73.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

KalVista Pharmaceuticals, Inc. (KALV) stock report — Zyberno Score 13/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:27.00
Market Cap:$1.47B

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.43B

Price Action & Momentum (1)

% of 52-Week High:100.0%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:-0.9%
Fundamental Growth Rate (g):0.6%

Margin Analysis (1)

Ebitda Margin:-226.3%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:1.5%
Latest Earnings Filed:2024-12-05

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-8.3%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:5.17x
Quick Ratio:5.10x
Cash Ratio:3.51x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-20.06x
Times Interest Earned:-20.06

Capital Structure (4)

Working Capital:253,388,000.00
Cash And Cash Equivalents:213,768,000.00
Long Term Debt:$172.21M
Net Debt:-$39.87M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $49.08M
Linear Growth: -8.3%
📊 Click to view full KALV Revenue analysis & methodology →
Cost Of Revenue Ttm:$3.08M

Profitability Breakdown (2)

$46.00M-$112.04M

Bottom Line Performance (3)

-$109.50M
Income Before Tax:-$23.49M
Ebitda Ttm:-111,068,000.00

Operating Expenses (5)

Operating Expenses:181,205,000.00
R And D Expense:62,401,000.00
Sga Expense:164,796,000.00
Income Tax Expense:$0.00
Interest Expense:5,586,000.00

Expense Ratios (3)

R And D To Revenue Percentage:4,457.2%
Sga To Revenue Percentage:11,771.1%
Ebitda Margin:-226.3%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$328.92M
Current Assets:$314.21M
Ppe Net:2,841,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:348,569,000.00
Current Liabilities:60,817,000.00
Long Term Debt:$172.21M
Short Term Debt:$1.69M

Equity & Capital (3)

Equity:-$19.65M
Retained Earnings:-$786.18M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:9,897,000.00
Inventory:4,002,000.00
Accounts Payable:34,022,000.00

Special Items (2)

Contract Liabilities:833,000.00
Stock Based Compensation:5,068,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$81.62M-$83.33M

Investment Activities (1)

Investing Cash Flow:-$901.00K

Financing Activities (3)

Financing Cash Flow:$1.47M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:210,582,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$2.01

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.90
Operating Cash Flow Per Share:-$1.50

Book Value & Capital (2)

Book Value Per Share:-$0.36
Cash Per Share:3.92

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.17x
Working Capital Turnover Ttm:0.19x

Receivables Management (2)

Receivables Turnover Ttm:4.96x
Days Sales Outstanding Ttm:73.61

Inventory Management (2)

Inventory Turnover Ttm:0.77x
Days Inventory Outstanding Ttm:474.11

Payables & Cash Cycle (2)

Days Payable Outstanding:4,030.52
Cash Conversion Cycle:-3,482.80
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.9%
Fundamental Growth Rate (g):0.6%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-8.3%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-14.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:KALV
Company Name:KalVista Pharmaceuticals, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:54.58M
Shares Outstanding Basic:54.58M
Shares Outstanding Diluted:54.58M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 17:09:48 UTC
Data Timestamp:2026-08-31T17:09:48.882287
Scroll to Top